Digitoxigenin presents an effective and selective antileishmanial action against Leishmania infantum and is a potential therapeutic agent for visceral leishmaniasis

Treatment for visceral leishmaniasis (VL) is hampered mainly by drug toxicity, their high cost, and parasite resistance. Drug development is a long and pricey process, and therefore, drug repositioning may be an alternative worth pursuing. Cardenolides are used to treat cardiac diseases, especially...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Parasitol Res
Egile Nagusiak: Freitas, Camila S., Oliveira-da-Silva, João A., Lage, Daniela P., Costa, Rafaella R., Mendonça, Débora V. C., Martins, Vívian T., Reis, Thiago A. R., Antinarelli, Luciana M. R., Machado, Amanda S., Tavares, Grasiele S. V., Ramos, Fernanda F., Coelho, Vinicio T. S., Brito, Rory C. F., Ludolf, Fernanda, Chávez-Fumagalli, Miguel A., Roatt, Bruno M., Ramos, Gabriela S., Munkert, Jennifer, Ottoni, Flaviano M., Campana, Priscilla R. V., Humbert, Maria V., Coimbra, Elaine S., Braga, Fernão C., Pádua, Rodrigo M., Coelho, Eduardo A. F.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Berlin Heidelberg 2020
Gaiak:
Treatment and Prophylaxis - Original Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7667010/
https://ncbi.nlm.nih.gov/pubmed/33191446
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00436-020-06971-2
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak